ClinicalTrials.gg

Program

DM-101PX

A development code.

Its studies are mostly in Rhinitis, Allergic, Seasonal, led by Desentum Oy.

Furthest: phase 2, since Sep 23, 20253 company-led studies, 1 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Desentum Oy31 open or runningphase 2since Sep 23, 2025Sep 6, 2023Mar 2027phase 1 · NCT07898800

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 6, 2023First study: phase 1 study in Birch Pollen AllergyFirst studyNCT06037148 · 30 enrolled · Canada
  2. Sep 23, 2025Phase 2 study in Birch Pollen AllergyNCT07254871 · 97 enrolled · Canada
  3. Oct 20, 2026Phase 1 study in Birch Pollen AllergyNCT07898800 · 40 planned · Germany

Ahead

  1. Mar 2027Primary completion: phase 1 study in Birch Pollen AllergyNCT07898800

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07898800Birch Pollen Allergy · Germany1RecruitingMar 202740
NCT07254871Birch Pollen Allergy · Canada2CompletedApr 15, 202697
NCT06037148Birch Pollen Allergy · Canada1CompletedMar 6, 202430

How it is read

Names in the registry

  • “DM-101PX”, 3 entries

Codes read as this program: DM101PX.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.